Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation

Kosorok, 1996, The incidence of cystic fibrosis, Stat Med, 15, 449, 10.1002/(SICI)1097-0258(19960315)15:5<449::AID-SIM173>3.0.CO;2-X Palomaki, 2004, Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population, Genet Med, 6, 405, 10.1097/01.GIM.0000139505.06194.39 Hamosh, 1998, Comparison of the clinical manifestations of cystic fibrosis in black and white patients, J Pediatr, 132, 255, 10.1016/S0022-3476(98)70441-X ECFS Patient Registry Burgel, 2015, Future trends in cystic fibrosis demography in 34 European countries, Eur Respir J, 46, 133, 10.1183/09031936.00196314 Kerem, 1989, Identification of the cystic fibrosis gene: genetic analysis, Science, 245, 1073, 10.1126/science.2570460 Dorfman R, for the CFMD/CFTR1 Team 1976, Report of the committee for a study for evaluation of testing for cystic fibrosis, J Pediatr, 88, 711 Sosnay, 2017, Diagnosis of cystic fibrosis in nonscreened populations, J Pediatr, 181S, S52, 10.1016/j.jpeds.2016.09.068 Cystic Fibrosis Foundation, 2015 Ren, 2015, Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening, Pediatrics, 135, 10.1542/peds.2014-3698 Parad, 2005, Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm, J Pediatr, 147, S78, 10.1016/j.jpeds.2005.08.017 Levy, 2015, New challenges in the diagnosis and management of cystic fibrosis, J Pediatr, 166, 1337, 10.1016/j.jpeds.2015.03.042 Tluczek, 2010, When the cystic fibrosis label does not fit: a modified uncertainty theory, Qual Health Res, 20, 209, 10.1177/1049732309356285 Tluczek, 2011, Psychosocial consequences of false-positive newborn screens for cystic fibrosis, Qual Health Res, 21, 174, 10.1177/1049732310382919 Nelson, 2011, Clinical practices for intermediate sweat tests following abnormal cystic fibrosis newborn screens, J Cyst Fibros, 10, 460, 10.1016/j.jcf.2011.07.002 Gilljam, 2004, Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood, Chest, 126, 1215, 10.1378/chest.126.4.1215 Masaryk, 1983, Pancreatitis as initial presentation of cystic fibrosis in young adults. A report of two cases, Dig Dis Sci, 28, 874, 10.1007/BF01317036 Marshak, 2011, Prevalence of rhinosinusitis among atypical cystic fibrosis patients, Eur Arch Otorhinolaryngol, 268, 519, 10.1007/s00405-010-1382-0 CFTR2@Johns Hopkins Sosnay, 2013, Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene, Nat Genet, 45, 1160, 10.1038/ng.2745 Sosnay, 2017, Applying cystic fibrosis transmembrane conductance regulator genetics and CFTR2 data to facilitate diagnoses, J Pediatr, 181S, S27, 10.1016/j.jpeds.2016.09.063 Ooi, 2012, Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?, Thorax, 67, 618, 10.1136/thoraxjnl-2011-201454 Farrell, 2008, Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report, J Pediatr, 153, S4, 10.1016/j.jpeds.2008.05.005 Borowitz, 2009, Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond, J Pediatr, 155 Munck, 2015, Cystic fibrosis screen positive, inconclusive diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening, J Cyst Fibros, 14, 706, 10.1016/j.jcf.2015.01.001 Bombieri, 2011, Recommendations for the classification of diseases as CFTR-related disorders, J Cyst Fibros, 10, S86, 10.1016/S1569-1993(11)60014-3 Farrell, 2017, Diagnosis of cystic fibrosis in screened populations, J Pediatr, 181S, S33, 10.1016/j.jpeds.2016.09.065 Ren, 2017, Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis, J Pediatr, 181S, S45, 10.1016/j.jpeds.2016.09.066 Rock, 2015, Sweat testing after abnormal CF newborn screening: a single center 20 year experience [Abstract], Pediatr Pulmonol, 50, 381 LeGrys, 2009 LeGrys, 2007, Cystic Fibrosis Foundation. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines, J Pediatr, 151, 85, 10.1016/j.jpeds.2007.03.002 Legrys, 2010, The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis, J Pediatr, 157, 1035, 10.1016/j.jpeds.2010.07.053 McColley, 2012, Improving sweat test QNS rates for infants with positive CF NBS in Illinois [Abstract], Pediatr Pulmonol, 47, 382 Abdulhamid, 2013, Reducing the rate of inadequate sweat testing for NBS in the state of Michigan [Abstract], Pediatr Pulmonol, 48, 377 Aqil, 2014, Implementation of a quality improvement program to improve sweat test performance in a pediatric hospital, Arch Pathol Lab Med, 138, 920, 10.5858/arpa.2013-0041-OA Eng, 2005, Sweat-testing in preterm and full-term infants less than 6 weeks of age, Pediatr Pulmonol, 40, 64, 10.1002/ppul.20235 Guimarães, 2012, Prevalence of hyponatremia at diagnosis and factors associated with the longitudinal variation in serum sodium levels in infants with cystic fibrosis, J Pediatr, 161, 285, 10.1016/j.jpeds.2012.01.052 Neville, 2009, Vitamin D in infants with cystic fibrosis diagnosed by newborn screening, J Paediatr Child Health, 45, 36, 10.1111/j.1440-1754.2008.01432.x Giglio, 1997, Failure to thrive: the earliest feature of cystic fibrosis in infants diagnosed by neonatal screening, Acta Paediatr, 86, 1162, 10.1111/j.1651-2227.1997.tb14836.x VanDevanter, 2016, Cystic fibrosis in young children: a review of disease manifestation, progression, and response to early treatment, J Cyst Fibros, 15, 147, 10.1016/j.jcf.2015.09.008 Borowitz, 2009, Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis, J Pediatr, 155, S73, 10.1016/j.jpeds.2009.09.001 Tluczek, 2005, Psychosocial risk associated with newborn screening for cystic fibrosis: parents' experience while awaiting the sweat-test appointment, Pediatrics, 115, 1692, 10.1542/peds.2004-0275 Ulph, 2015, Parents' responses to receiving sickle cell or cystic fibrosis carrier results for their child following newborn screening, Eur J Hum Genet, 23, 459, 10.1038/ejhg.2014.126 Comeau, 2007, Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report, Pediatrics, 119, 10.1542/peds.2006-1993 Tluczek, 2006, Newborn screening for cystic fibrosis: parents' preferences regarding counseling at the time of infants' sweat test, J Genet Couns, 15, 277, 10.1007/s10897-006-9031-x Rosenstein, 1998, The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel, J Pediatr, 132, 589, 10.1016/S0022-3476(98)70344-0 Therrell, 2012, Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: challenges in newborn dried blood spot screening, Mol Genet Metab, 106, 1, 10.1016/j.ymgme.2012.02.013 Rock, 2011, Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening, Pediatr Pulmonol, 46, 1166, 10.1002/ppul.21509 Watson, 2004, Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel, Genet Med, 6, 387, 10.1097/01.GIM.0000139506.11694.7C Cordovado, 2012, CFTR mutation analysis and haplotype associations in CF patients, Mol Genet Metab, 105, 249, 10.1016/j.ymgme.2011.10.013 Bergougnoux, 2016, A false positive newborn screening result due to a complex allele carrying two frequent CF-causing variants, J Cyst Fibros, 15, 309, 10.1016/j.jcf.2016.04.003 Kiesewetter, 1993, A mutation in CFTR produces different phenotypes depending on chromosomal background, Nat Genet, 5, 274, 10.1038/ng1193-274 Thauvin-Robinet, 2009, The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening, J Med Genet, 46, 752, 10.1136/jmg.2009.067215 Boyle, 2013, A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect, Lancet Respir Med, 1, 158, 10.1016/S2213-2600(12)70057-7 Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. Augarten, 1993, Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C→T mutation, Lancet, 342, 25, 10.1016/0140-6736(93)91885-P Highsmith, 1994, A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations, N Engl J Med, 331, 974, 10.1056/NEJM199410133311503 Stewart, 1995, Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis, Am J Respir Crit Care Med, 151, 899, 10.1164/ajrccm/151.3_Pt_1.899 Feldmann, 2003, CFTR genotypes in patients with normal or borderline sweat chloride levels, Hum Mutat, 22, 340, 10.1002/humu.9183 Keating, 2010, Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis, Chest, 137, 1157, 10.1378/chest.09-1352 Goubau, 2009, Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis, Thorax, 64, 683, 10.1136/thx.2008.104752 Naehrlich, 2014, Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey, J Cyst Fibros, 13, 24, 10.1016/j.jcf.2013.08.006 Hirtz, 2004, CFTR Cl− channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis, Gastroenterology, 127, 1085, 10.1053/j.gastro.2004.07.006 Derichs, 2010, Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data, Thorax, 65, 594, 10.1136/thx.2009.125088 Ooi, 2014, Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis?, Ann Am Thorac Soc, 11, 562, 10.1513/AnnalsATS.201311-412OC Sermet-Gaudelus, 2010, Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis, Thorax, 65, 539, 10.1136/thx.2009.123422 De Boeck, 2013, CFTR biomarkers: time for promotion to surrogate end-point, Eur Respir J, 41, 203, 10.1183/09031936.00057512 Bagheri-Hanson, 2014, Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study, BMC Pulm Med, 14, 156, 10.1186/1471-2466-14-156 De Jonge, 2004, Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers, J Cyst Fibros, 3, 159, 10.1016/j.jcf.2004.05.034 De Boeck, 2011, New clinical diagnostic procedures for cystic fibrosis in Europe, J Cyst Fibros, 10, S53, 10.1016/S1569-1993(11)60009-X Farrell, 2017, Cystic fibrosis diagnostic challenges over 4 decades: historical perspectives and lessons learned, J Pediatr, 181S, S16, 10.1016/j.jpeds.2016.09.067 Castellani Ooi, 2015, Inconclusive diagnosis of cystic fibrosis after newborn screening, Pediatrics, 135, 10.1542/peds.2014-2081 Levy, 2016, Refining the continuum of CFTR-associated disorders in the era of newborn screening, Clin Genet, 89, 539, 10.1111/cge.12711 Kharrazi, 2015, Newborn screening for cystic fibrosis in California, Pediatrics, 136, 1062, 10.1542/peds.2015-0811 Rock, 1989, Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test, Pediatr Pulmonol, 6, 42, 10.1002/ppul.1950060111 Massie, 2006, Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing, Arch Dis Child, 91, 222, 10.1136/adc.2005.081349 WHO WHO